Cargando…
Clinical outcomes in cancer patients with COVID‐19
BACKGROUND: Early reports on cancer patients with coronavirus disease 2019 (COVID‐19) corroborated speculation that cancer patients are at increased risk for becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and developing severe COVID‐19. However, cancer patients a...
Autores principales: | Sawyers, Amelia, Chou, Margaret, Johannet, Paul, Gulati, Nicholas, Qian, Yingzhi, Zhong, Judy, Osman, Iman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420395/ https://www.ncbi.nlm.nih.gov/pubmed/34409775 http://dx.doi.org/10.1002/cnr2.1413 |
Ejemplares similares
-
Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer
por: Johannet, Paul, et al.
Publicado: (2020) -
Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients
por: Johannet, Paul, et al.
Publicado: (2021) -
Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors
por: Gulati, Nicholas, et al.
Publicado: (2020) -
Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors
por: Gulati, Nicholas, et al.
Publicado: (2021) -
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)